Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Peace13on Aug 02, 2018 6:42pm
108 Views
Post# 28407644

New Name?

New Name?BTH owning Nash Pharma.  Sort of like adding another story onto the house. 
Seems the Bullrun Team is adding another company under the BTH umbrella.
NASH are onto something big with treatment of NASH (Non-Alcoholic Steatohepatitis), Chronic Kindney Disease (CKD) and IBD.
The connection is the medical application.  The diagnostic tool and treatment of diseases NASH are focused on, the BTH tool will be able to detect.  That is the goal. A lot more work to do, but the concept is viable with this team.
I like this.  Leads me to believe the advancement by the YOST team on FAIM technology used for Cannabix has reached a place where some attention can return to BTH and their growth.
If this is the case, great news pending for Cannabix, the device is very close to reaching Canadian Government standards.  And a surge in sp for BTH as increased volume comes to BTH through BLO.

   
Bullboard Posts